A Phase 1 interventional study of Cobimetinib in Healthy Volunteers, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will be an open-label, randomized, 3-way, 6-sequence crossover study in healthy participants for determining the relative bioavailability of the tablet formulation to the capsule formulation and the effect of food on the relative bioavailability of the tablet formulation.
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliter (mL) room temperature water after at least an 8-hour fast, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard Food and Drug Administration (FDA) high-fat meal, in third intervention period. The washout period between each period will be a minimum of 10 days.
Drug: Cobimetinib
Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib administered will be orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
Drug: Cobimetinib
Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in third intervention period.
Drug: Cobimetinib
Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
Drug: Cobimetinib
Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
Drug: Cobimetinib
Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
Drug: Cobimetinib
Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
Also known as: GDC-0973, XL518
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).
Time frame: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose
Maximum Observed Plasma Concentration (Cmax)
Time frame: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose
Minimum Observed Plasma Concentration (Cmin)
Time frame: Day 1 at 0 hour (predose)
Apparent Oral Clearance (CL/F)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose
Apparent Volume of Distribution (V/F)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Day 1 at 0 hour (predose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 hours postdose
| Milestone | Treatment A First, Then Treatment B, Followed by Treatment C | Treatment A First, Then Treatment C, Followed by Treatment B | Treatment B First, Then Treatment A, Followed by Treatment C | Treatment B First, Then Treatment C, Followed by Treatment A | Treatment C First, Then Treatment A, Followed by Treatment B | Treatment C First, Then Treatment B, Followed by Treatment A |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 3 | 4 |
| Completed | 3 | 3 | 4 | 3 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment A First, Then Treatment B, Followed by Treatment C | Treatment A First, Then Treatment C, Followed by Treatment B | Treatment B First, Then Treatment A, Followed by Treatment C | Treatment B First, Then Treatment C, Followed by Treatment A | Treatment C First, Then Treatment A, Followed by Treatment B | Treatment C First, Then Treatment B, Followed by Treatment A |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 3 | 4 |
| Completed | 3 | 3 | 4 | 3 | 2 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Treatment A First, Then Treatment B, Followed by Treatment C | Treatment A First, Then Treatment C, Followed by Treatment B | Treatment B First, Then Treatment A, Followed by Treatment C | Treatment B First, Then Treatment C, Followed by Treatment A | Treatment C First, Then Treatment A, Followed by Treatment B | Treatment C First, Then Treatment B, Followed by Treatment A |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 2 | 4 |
| Completed | 3 | 3 | 4 | 3 | 2 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment A First, Then Treatment B, Followed by Treatment C | Treatment A First, Then Treatment C, Followed by Treatment B | Treatment B First, Then Treatment A, Followed by Treatment C | Treatment B First, Then Treatment C, Followed by Treatment A | Treatment C First, Then Treatment A, Followed by Treatment B | Treatment C First, Then Treatment B, Followed by Treatment A |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 2 | 4 |
| Completed | 3 | 3 | 4 | 3 | 2 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment A First, Then Treatment B, Followed by Treatment C | Treatment A First, Then Treatment C, Followed by Treatment B | Treatment B First, Then Treatment A, Followed by Treatment C | Treatment B First, Then Treatment C, Followed by Treatment A | Treatment C First, Then Treatment A, Followed by Treatment B | Treatment C First, Then Treatment B, Followed by Treatment A |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 2 | 4 |
| Completed | 3 | 3 | 4 | 3 | 2 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).
| nanograms*hours/milliliter (ng*hr/mL) | Cobimetinib One 20 mg Tablet [Fasted] | Cobimetinib Four 5 mg Capsules [Fasted] | Cobimetinib One 20 mg Tablet [Fed] |
|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) | 780 ± 34.7 | 717 ± 45.1 | 858 ± 42.4 |
| nanograms per milliliter (ng/mL) | Cobimetinib One 20 mg Tablet [Fasted] | Cobimetinib Four 5 mg Capsules [Fasted] | Cobimetinib One 20 mg Tablet [Fed] |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 16.0 ± 33.5 | 14.9 ± 45.9 | 17.2 ± 43.1 |
| ng/mL | Cobimetinib One 20 mg Tablet [Fasted] | Cobimetinib Four 5 mg Capsules [Fasted] | Cobimetinib One 20 mg Tablet [Fed] |
|---|---|---|---|
| Minimum Observed Plasma Concentration (Cmin) | 0.307 ± 46.6 | 0.36 ± 56.6 | 0.361 ± 60.3 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| Liters per hour (L/hr) | Cobimetinib One 20 mg Tablet [Fasted] | Cobimetinib Four 5 mg Capsules [Fasted] | Cobimetinib One 20 mg Tablet [Fed] |
|---|---|---|---|
| Apparent Oral Clearance (CL/F) | 25.6 ± 34.7 | 25.2 ± 45.1 | 23.3 ± 42.4 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| Liters (L) | Cobimetinib One 20 mg Tablet [Fasted] | Cobimetinib Four 5 mg Capsules [Fasted] | Cobimetinib One 20 mg Tablet [Fed] |
|---|---|---|---|
| Apparent Volume of Distribution (V/F) | 2103 ± 40.4 | 1930 ± 50.2 | 1900 ± 38.3 |
Collected over Adverse events were recorded from start of study treatment in first period to end of last period (up to 30 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cobimetinib One 20 mg Tablet [Fasted] | — | 0/19 (0%) | 6/19 (31.6%) |
| Cobimetinib Four 5 mg Capsules [Fasted] | — | 0/19 (0%) | 9/19 (47.4%) |
| Cobimetinib One 20 mg Tablet [Fed] | — | 0/20 (0%) | 8/20 (40%) |
| Event | Cobimetinib One 20 mg Tablet [Fasted] | Cobimetinib Four 5 mg Capsules [Fasted] | Cobimetinib One 20 mg Tablet [Fed] |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/19 | 2/19 | 1/20 |
| VomitingGastrointestinal disorders | 0/19 | 2/19 | 0/20 |
| Back painMusculoskeletal and connective tissue disorders | 0/19 | 2/19 | 0/20 |
| Dry skinSkin and subcutaneous tissue disorders | 0/19 | 2/19 | 0/20 |
| HeadacheNervous system disorders | 2/19 | 2/19 | 2/20 |
| Abdominal discomfortGastrointestinal disorders | 0/19 | 1/19 | 2/20 |
| DiarrhoeaGastrointestinal disorders | 0/19 | 1/19 | 1/20 |
| DysphagiaGastrointestinal disorders | 1/19 | 0/19 | 1/20 |
| Abdominal pain upperGastrointestinal disorders | 0/19 | 1/19 | 0/20 |
| Faecal incontinenceGastrointestinal disorders | 0/19 | 1/19 | 0/20 |
All enrolled participants
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 36 (19 to 52) |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 7 |
| Male | 13 |
No study locations are listed for this record.
Ran from Dec 2010 to primary completion in Jan 2011, 1 month.
Results were first posted in Jul 2016, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cobimetinib